Rituximab is effective for all four clinical profiles of immunoglobulin G4-related disease (IgG4-RD), but two IgG4-RD profiles, or phenotypes, may show poorer responses, according to a multicenter study in Europe. “Patients in the retroperitoneal and aortic and head and neck-limited phenotypes may be less responsive,” the researchers said, and…
Read more
Dear 16-year-old me, I chose to write to you instead of the 5- and 8-year-old versions of you because all I’d do is hold the younger versions and whisper that you’re loved. I know you’re tired. You’re angry, and you feel misunderstood. You’ve lived your whole life through pain and…
Zenas Biopharma has secured up to $300 million from Royalty Pharma to accelerate the development of obexelimab, its investigational treatment that could provide much-needed relief for people with immunoglobulin G4-related disease (IgG4-RD). In exchange, Royalty Pharma will receive a share of royalties on sales of obexelimab, which is…
Get regular updates to your inbox.
